



Pr Monique Minnema

Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht.

She is the medical head of the hematology research team which supervises more than 20 clinical studies. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias and she was appointed full professor of hematology in 2019.

Prof Dr Minnema is an active member of the HOVON working parties for Multiple Myeloma, Lymphoma and the vice president of the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016.



Pr Giovanni Palladini

Pr Palladini is the director of the Amyloidosis Research and Treatment Center at the Foundation "IRCCS Policlinico San Matteo", Pavia, Italy, and the president of the International Society of Amyloidosis.

With validated staging systems and response criteria and with an increasing number of randomized clinical trials, systemic amyloidoses, once orphan, neglected diseases are entering the realm of evidence-based medicine.

To make these important clinical advancements accessible to the largest possible number of patients, a collaboration between academia, pharmaceutical companies, scientific societies, and patient association is vital. The International Society of Amyloidosis welcomes and supports the World Amyloidosis Day initiative and is looking forward to a fruitful collaboration and synergism with the Amyloidosis Alliance.





Pr Julian Gillmore

Professor Julian Gillmore undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

He was appointed Centre Head at UCL's Centre for Amyloidosis & Acute Phase Proteins in 2019 and is research lead at the UK National Amyloidosis Centre.



Dr Laura Obici

Consultant at the Amyloid Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. She was awarded her Medicine and Surgery degree with honours from the University of Pavia in 1994, and was later awarded a Master's degree in molecular medicine and genetic epidemiology. In 2000, she became a specialist in Internal Medicine at the University of Pavia.

Dr Obici's main research interests include the molecular mechanisms of systemic amyloidosis, the prognosis and therapy of systemic amyloidoses, and the genetic basis of hereditary amyloidoses and hereditary periodic fever syndromes. She was Secretary of the International Society for Amyloidosis from 2010 to 2014 and is Principal Investigator/Co-investigator for several ongoing clinical trials of novel drugs for the treatment of amyloidosis. She has co-authored 149 peer-reviewed publications in international journals.





Pr Thibaud DAMY

Head of the French Referral Center for Cardiac Amyloidosis.
Past president of French Heart Failure and Cardiomyopathy Group of the French Society of Cardiology and European Heart Failure Association.

Professor Damy's main field of interests are heart failure and amyloidosis, extending from its epidemiology and physiopathology through to its diagnosis and treatment. His particular current interests include novel cardiac diagnostic markers, from biology to imaging. He is a co-author of 172 articles of which 100 are focusing on amyloidosis.

In 2011, he was appointed Professor in Cardiology and became the Head of the Heart Failure and Cardiomyopathy unit at Assistance Publique, Hôpitaux de Paris, France. In 2009, Professor Damy created the "Mondor Amyloidosis Network", which involves all the clinical facilities for the diagnosis and treatment of amyloidosis, in addition to a clinical research team. It rapidly became an important multidisciplinary network involving more than 40 healthcare professionals in the hospital. In 2014, they created the GRC Amyloid Research Institute. Since 2010, more than 5.900 patients have been referred to the centre



Dr Pablo Garcia-Pavia

Dr Pablo García-Pavia is the director of the Inherited Cardiac Diseases and Heart Failure Unit at the Department of Cardiology of Hospital Universitario Puerta de Hierro in Madrid, Spain.

The Unit is designed as national reference unit (CSUR) for inherited cardiovascular diseases by the Spanish Ministry of Health and also acts as a European reference center for rare cardiovascular diseases (ERN).

His areas of research include heart failure, amyloidosis and cardiomyopathies. He is former member of ESC Council on Basic Research, former member of the Nucleus of ESC working group on myocardial and pericardial diseases, and former president of Spanish Society of Cardiology's working group on inherited cardiac diseases. He has published >190 articles in peer-reviewed journals.





Pr Ashutosh Wechalekar

Senior lecturer and honorary consultant haematologist at University College London and the Royal Free London NHS Foundation Trust. He trained in haematology in the UK and Canada. In 2004, he joined the UK National Amyloidosis Centre as an honorary senior research fellow funded by a grant from the Leukaemia Research Fund. In 2007 he was appointed senior lecturer/honorary consultant in the National Amyloidosis Centre and department of haematology.

His academic and clinical interests are focused on amyloidosis and multiple myeloma. In particular, he is interested in characterisation and treatment of systemic AL amyloidosis as well as multiple myeloma, including clinical trials of new and novel agents in these disorders. He has published widely in these areas.



Dr Márcia Waddington-Cruz

CEPARM. National Amyloidosis Referral Center. Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Brazil
Dr Waddington-Cruz has also been responsible for the Brazilian referral centre for TTR-FAP, the Centro de Estudos em paramiloidose Antônio Rodrigues de Mello (CEPARM) since 1990. CEPARM oversees more than 400 TTR-FAP patients. Dr Waddington-Cruz participated in the development programme for tafamidis, patisiran, vutrisiran, inotersen, and eplontersen as well as serving on several Advisory Boards and Steering Committees in the field of ATTR. CEPARM was the first amyloidosis referral centre established in Brazil and Dr. Waddington-Cruz faced several difficulties to create and maintain a multidisciplinary team devoted to amyloidosis.

She also struggled for the centre to have a space and equipment to properly receive patients coming from all over Latin America into the hard reality of the Public Health system.

Dr Waddington-Cruz was appointed President of the Transthyretin Amyloidosis Outcomes Survey (THAOS) scientific board in 2016 until 2019. She worked together with the Ministry of Health of Brazil for more than 4 years to write the first guidelines for treatment of Amyloidosis and to make tafamidis be included in the roll of drugs delivered by the Public Health system for Amyloidosis all over Brazil. Dr. Waddington-Cruz has been cooperating and working close with the patient's association (ABPAR) since its beginning back in 1989.





Pr Sophie GEORGIN-LAVIALLE

Internal Medicine department, Tenon hospital, Paris, France

Sophie Georgin-Lavialle has a medical doctorate in Internal medicine and a scientific doctorate in Immunology. She is leading the French national reference center for inflammatory (AA) amyloidosis and adult auto-inflammatory diseases. She works on the clinical aspects of these diseases and on translational research on inflammation, innate immunity and AA amyloidosis.

She is coordinating the clinical research group on AA amyloidosis of Sorbonne University, Paris, France. She is developing tools for therapeutic education on AA amyloidosis with the French patients association for amyloidosis. She is working with francophone colleagues on pedagogic aspects on AA amyloidosis to decrease diagnostic delay in this variety of amyloidosis.



Pr Angela Dispenzieri

Rochester, Minnesota

Angela Dispenzieri, M.D., conducts research in plasma cell disorders, including multiple myeloma, amyloidosis, POEMS syndrome and other rare plasma cell disorders.

Dr. Dispenzieri's joint appointments in hematology and clinical chemistry are conducive to clinical and translational research in these fields. She also specializes in clinical trials and stem cell transplantation.

Focus areas:

Application of mass spectrometry to the diagnosis and prognosis of patients with plasma cell disorders
Immunoglobulin light chain (AL) amyloidosis. .
POEMS syndrome. .
Multiple myeloma.





Pr David Adams

Neurologist, head of Department of Neurology (CHU Bicetre, APHP) since 2009. Founder of national reference of Familial Amyloid Polyneuropathy (FAP) and other rare peripheral neuropathies (NNERf) in 2005, certified by the French Health Ministry. He described the first cases of amyloid neuropathies in France in 1990, reported the efficacy of first 45 Liver transplantation in FAP in France in 2000, the efficacy of RNAi therapy for ATTRv polyneuropathy in 2018

He is working on early diagnosis of disease in carriers of ATTR variants, and preventive therapy. Hr organized the 1st European ATTR Amyloidosis Meeting for Patients and Doctors in 2017. Member of French society of Peripheral neuropathy, member of the board of European Academy of Neurology, member of Peripheral Nerve Society and International Society of Amyloidosis. He published more than 170 publications in international journals.



Dr Vincent ALGALARRONDO

Hôpital Bichat Claude Bernard Cardiology Department Paris, FRANCE.

- JESFC 2007: Best poster: "Phenotype-genotype correlation of conduction disorders in familial amyloid polyneuropathy"
- Europace 2009: Young Investigator award: "Paroxysmic AV block and cardiac pacing in familial amyloid polyneuropathy")
- Member of the writing committee of the position paper of the HAS (Haute Autorité de Santé) for the diagnosis and the management of patients with hereditary transthyretin amyloidosis (2015-2016).

Expert for the ANSM (Agence Nationale de sécurité du médicament et des produits de santé) for evaluating new treatments in transthyretin amyloidosis . Member of t he Directory Board of the GRRC (Groupe de réflexion sur la recherche cardiovasculaire) since 2018 . Congress president of the "Printemps de la Cardiologie 2021", an e-congress that took place in May 2021 and gathered 480 researchers in the field of Cardiology

